Dctx/estm weekly therapy continued by vp-16/estm treatment in HRPC patients (GS>6) (CROSBI ID 525704)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Tarle, Marko ; Kovačić, Ksenija ; Kraljić, Ivo ; Kusić, Zvonko.
engleski
Dctx/estm weekly therapy continued by vp-16/estm treatment in HRPC patients (GS>6)
Docetaxel applied with estramustine and/prednisone is the mostly chosen treatment in HRPC patients. The administration of dctx in weekly or q3w doses remains an unsolved question. At that time we found slightly better results during 6 cycles of weekly application of dctx according to monitoring data.
HRPC; PRPC; docetaxel therapy; weekly or q3w; time to progression
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
49-49-x.
2006.
objavljeno
Podaci o matičnoj publikaciji
Book of Abstracts, 16th International Prostate Cancer Update, Beaver Creek, Colorado
David E Crawford
Denver (CO): University of Denver
Podaci o skupu
16th International Prostate Cancer Update, Beaver Creek, Colorado, January 18-22, 2006.
poster
18.01.2006-22.01.2006
Beaver Creek (CO), Sjedinjene Američke Države
